Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ingenol mebutate

Drug Profile

Ingenol mebutate

Alternative Names: 3-Ingenyl angelate; I3A; Ingenol-3-angelate; PEP-005; PEP005-015; Picato

Latest Information Update: 28 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer LEO Pharma; Peplin
  • Class Antineoplastics; Ingenols; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Warts
  • No development reported Basal cell cancer; Bladder cancer; Leukaemia; Squamous cell cancer

Most Recent Events

  • 28 May 2019 No recent reports of development identified for phase-I development in Warts in USA (Topical, Gel)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Actinic keratosis(Combination therapy) in USA (Topical, Gel)
  • 30 Mar 2017 LEO Pharma completes a phase I trial in Warts in USA (Topical) (NCT02748902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top